198 related articles for article (PubMed ID: 20022572)
21. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
23. Febuxostat: a new treatment for hyperuricaemia in gout.
Edwards NL
Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
[TBL] [Abstract][Full Text] [Related]
24. Rasburicase in the prevention and treatment of tumour lysis syndrome.
Mayne N; Keady S; Thacker M
Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
[TBL] [Abstract][Full Text] [Related]
25. [Gout].
Gröbner W; Zöllner N
Z Rheumatol; 2004 Feb; 63(1):2-9. PubMed ID: 14991273
[TBL] [Abstract][Full Text] [Related]
26. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
27. The management of tumor lysis syndrome.
Rampello E; Fricia T; Malaguarnera M
Nat Clin Pract Oncol; 2006 Aug; 3(8):438-47. PubMed ID: 16894389
[TBL] [Abstract][Full Text] [Related]
28. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
29. Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature.
Teo WY; Loh TF; Tan AM
Ann Acad Med Singap; 2007 Aug; 36(8):679-83. PubMed ID: 17767339
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency.
Torres RJ; Prior C; Puig JG
Metabolism; 2007 Sep; 56(9):1179-86. PubMed ID: 17697859
[TBL] [Abstract][Full Text] [Related]
31. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
[TBL] [Abstract][Full Text] [Related]
32. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
Holdsworth MT; Nguyen P
Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
[TBL] [Abstract][Full Text] [Related]
33. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
Perez-Ruiz F; Calabozo M; Erauskin GG; Ruibal A; Herrero-Beites AM
Arthritis Rheum; 2002 Dec; 47(6):610-3. PubMed ID: 12522834
[TBL] [Abstract][Full Text] [Related]
34. Use of single-dose rasburicase in an obese female.
Arnold TM; Reuter JP; Delman BS; Shanholtz CB
Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
[TBL] [Abstract][Full Text] [Related]
35. Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome.
Brant JM
Clin J Oncol Nurs; 2002; 6(1):12-6. PubMed ID: 11842483
[TBL] [Abstract][Full Text] [Related]
36. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
[TBL] [Abstract][Full Text] [Related]
37. Management of hyperuricemia with rasburicase review.
de Bont JM; Pieters R
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
[TBL] [Abstract][Full Text] [Related]
38. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
Rényi I; Bárdi E; Udvardi E; Kovács G; Bartyik K; Kajtár P; Masát P; Nagy K; Galántai I; Kiss C
Pathol Oncol Res; 2007; 13(1):57-62. PubMed ID: 17387390
[TBL] [Abstract][Full Text] [Related]
39. Frequency of hyperuricemia and effect of calcineurin inhibitors on serum uric acid levels in liver transplanted children.
Tumgor G; Arikan C; Kilic M; Aydogdu S
Pediatr Transplant; 2006 Sep; 10(6):665-8. PubMed ID: 16911488
[TBL] [Abstract][Full Text] [Related]
40. Tumour lysis syndrome: new therapeutic strategies and classification.
Cairo MS; Bishop M
Br J Haematol; 2004 Oct; 127(1):3-11. PubMed ID: 15384972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
